Skip to Content

Opsumit Approval History

Opsumit (macitentan) is a dual endothelin receptor antagonist for the treatment of patients with pulmonary arterial hypertension.

Development History and FDA Approval Process for Opsumit

Oct 18, 2013Approval FDA Approves Opsumit to Treat Pulmonary Arterial Hypertension
Dec 14, 2012Actelion Announces acceptance of the New Drug Application for macitentan by the US Food and Drug Administration
Oct 22, 2012Actelion submits a New Drug Application to the FDA for macitentan (Opsumit) for the treatment of patients with pulmonary arterial hypertension

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.